New Version goBalto Activate Available
goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, today announced its latest version of goBalto Activate.
goBalto, a provider of cloud-based clinical study startup solutions, announced its latest version of goBalto Activate. This first major release of 2015 offers new features that further accelerate clinical study startup.New capabilities focus on enhanced document management, business process improvement, and alerting, which include:
- expired document management
- alerts that highlight opportunities to improve cycle times and track activities and milestones
- automated workflows that drive the entire process until documents are ready for eTMF filing
- ability for sites to complete activities in seconds using the new Activate LITE interface
- an API enhancement to support seamless integration with investigator portals
Read the full release here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
